Whole-exome sequencing found that mutations of the NF1 gene are an important driver mutation in melanoma. It is the third most frequently mutated gene in melanoma, behind BRAF and NRAS, a finding that could yield more targeted therapies in the future.
MRV Research
Novel Clinical Trial for BRAFV600-Advanced Melanoma Initiates Patient Recruitment
The ECOG-ACRIN Cancer Research Group recently announced it will begin patient enrolment in its Phase III cancer clinical trial that will compare two differently acting treatments that have previously shown to be effective in the treatment of patients with advanced melanoma.
Women more likely to survive melanomas
WOMEN are more likely than men to survive a melanoma diagnosis regardless of the stage of the tumour at diagnosis, new research shows.
The joint study* by University of Queensland, Cancer Council Queensland and QIMR Berghofer found survival rates were higher for females for nearly all tumour stages, including both thin and thick invasive melanomas.
Castle Biosciences financing supports gene test for cutaneous melanoma metastatic risk
Castle Biosciences announced it has raised $11.7 million at the closing of the first tranche of a $20 million Series F financing, according to a press release